diclofenac has been researched along with Peptic Ulcer in 67 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 9.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 9.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "To compare the gastroduodenal safety of lumiracoxib with ibuprofen and celecoxib in patients with rheumatoid arthritis." | 9.11 | Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. ( Gimona, A; Hawkey, C; Kivitz, AJ; Nayiager, S; Schimansky, T; Thurston, HJ, 2004) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 9.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| " Health-care resource utilization and the costs of these resources were compared from the perspective of the UK National Health Service using data obtained in a 6-month clinical trial of oral valdecoxib 20 mg once daily and diclofenac 75 mg twice daily for the symptomatic treatment of rheumatoid arthritis." | 9.10 | Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. ( Niculescu, L; Peña, B; von Scheele, B; Wong, J, 2003) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 9.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| "To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid arthritis (RA)." | 9.10 | Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. ( Pavelka, K; Recker, DP; Verburg, KM, 2003) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 9.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 9.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "The objective of our study was to estimate the cost effectiveness of treatment with a fixed-dose combination of diclofenac and misoprostol compared with diclofenac monotherapy in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in rheumatoid arthritis (RA) patients." | 9.08 | The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. ( Al, MJ; Michel, BC; Rutten, FF, 1996) |
| "The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients." | 9.08 | Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. ( Agrawal, NM; Erhardt, LJ; Geis, GS; Van Kerckhove, HE, 1995) |
| "To compare the efficacy and gastroduodenal safety of a fixed-dose combination of diclofenac sodium 50 mg and misoprostol 200 micrograms twice daily with those of piroxicam 10 mg twice daily and naproxen 375 mg twice daily in patients with osteoarthritis." | 9.07 | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. ( Bruyn, GA; Geis, GS; Melo Gomes, JA; Roth, SH; Woods, EM; Zeeh, J, 1993) |
| "A double-blind, randomized, parallel group study was conducted to compare the gastroduodenal safety and antiarthritic efficacy of a fixed combination of diclofenac 50 mg and misoprostol 200 micrograms with that of a combination of diclofenac 50 mg and placebo in patients with osteoarthritis." | 9.07 | The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. ( Bolten, W; Geis, GS; Gomes, JA; Stead, H, 1992) |
| "Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in five multicenter, double-blind parallel controlled investigations." | 9.06 | Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. ( Caldwell, JR, 1986) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 8.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| " A stratified analysis according to the prescription of diclofenac alone or in combination with PPI showed that diclofenac prescriptions increased the risk for hospitalisation due to peptic ulcer significantly (adjusted OR 2." | 7.74 | Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. ( Gothe, H; Grass, U; Häussler, B; Höer, A; Schiffhorst, G; Sterzel, A, 2007) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 7.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 6.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 5.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| "To test whether treatment with celecoxib reduces the incidence of gastroduodenal ulcers compared to diclofenac in Asian patients with osteoarthritis (OA) or rheumatoid arthritis (RA) with minimal significant risk factors." | 5.14 | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. ( Cheng, TT; Cheung, R; Dong, Y; Feng, H; Lai, K; Lau, CS; Lin, HY; Parsons, B, 2010) |
| "To compare the gastroduodenal safety of lumiracoxib with ibuprofen and celecoxib in patients with rheumatoid arthritis." | 5.11 | Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. ( Gimona, A; Hawkey, C; Kivitz, AJ; Nayiager, S; Schimansky, T; Thurston, HJ, 2004) |
| "The Therapeutic Arthritis Research and Gastrointestinal Event Trial was a randomized, double-blind, 52-week study of lumiracoxib 400 mg once daily (two to four times the recommended dose for osteoarthritis) versus naproxen 500 mg twice daily or ibuprofen 800 mg three-times daily in patients with osteoarthritis." | 5.11 | Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. ( Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P, 2004) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 5.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 5.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| "To compare the efficacy and upper gastrointestinal (GI) safety of valdecoxib 20 and 40 mg daily with those of diclofenac 75 mg slow release (SR) twice daily in treating rheumatoid arthritis (RA)." | 5.10 | Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. ( Pavelka, K; Recker, DP; Verburg, KM, 2003) |
| " Health-care resource utilization and the costs of these resources were compared from the perspective of the UK National Health Service using data obtained in a 6-month clinical trial of oral valdecoxib 20 mg once daily and diclofenac 75 mg twice daily for the symptomatic treatment of rheumatoid arthritis." | 5.10 | Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. ( Niculescu, L; Peña, B; von Scheele, B; Wong, J, 2003) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 5.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| "To evaluate the efficacy and gastrointestinal safety of nabumetone and diclofenac in the treatment of elderly patients with osteoarthritis, participating in a 3-month efficacy trial." | 5.09 | Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. ( DeLapp, R; Kaine, J; Morgan , GJ; Palmer, R, 2001) |
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 5.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "The objective of our study was to estimate the cost effectiveness of treatment with a fixed-dose combination of diclofenac and misoprostol compared with diclofenac monotherapy in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in rheumatoid arthritis (RA) patients." | 5.08 | The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis. ( Al, MJ; Michel, BC; Rutten, FF, 1996) |
| "The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients." | 5.08 | Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study. ( Agrawal, NM; Erhardt, LJ; Geis, GS; Van Kerckhove, HE, 1995) |
| "To compare the efficacy and gastroduodenal safety of a fixed-dose combination of diclofenac sodium 50 mg and misoprostol 200 micrograms twice daily with those of piroxicam 10 mg twice daily and naproxen 375 mg twice daily in patients with osteoarthritis." | 5.07 | Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. ( Bruyn, GA; Geis, GS; Melo Gomes, JA; Roth, SH; Woods, EM; Zeeh, J, 1993) |
| "A double-blind, randomized, parallel group study was conducted to compare the gastroduodenal safety and antiarthritic efficacy of a fixed combination of diclofenac 50 mg and misoprostol 200 micrograms with that of a combination of diclofenac 50 mg and placebo in patients with osteoarthritis." | 5.07 | The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis. ( Bolten, W; Geis, GS; Gomes, JA; Stead, H, 1992) |
| "Diclofenac sodium is a nonsteroidal, anti-inflammatory drug that has been studied in the United States for the treatment of rheumatoid arthritis in 681 patients, 468 of whom were enrolled in five multicenter, double-blind parallel controlled investigations." | 5.06 | Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States. ( Caldwell, JR, 1986) |
| "A prespecified pooled intent-to-treat analysis of three double-blind randomised comparisons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoarthritis or rheumatoid arthritis was done for upper gastrointestinal clinical events (bleeding, perforation, obstruction, or ulcer) and the subset of complicated events (perforation, obstruction, witnessed ulcer bleeding, or significant bleeding)." | 4.84 | Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. ( Cannon, CP; Cryer, B; Curtis, SP; Kaur, A; Laine, L, 2007) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| "The combined formulation of diclofenac/misoprostol provides effective relief of pain and inflammation, with a 2- to 3-fold lower incidence of NSAID-associated gastroduodenal ulcers than diclofenac monotherapy." | 4.80 | Diclofenac/misoprostol. Pharmacoeconomic implications of therapy. ( Lamb, HM; Plosker, GL, 1999) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| " A stratified analysis according to the prescription of diclofenac alone or in combination with PPI showed that diclofenac prescriptions increased the risk for hospitalisation due to peptic ulcer significantly (adjusted OR 2." | 3.74 | Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. ( Gothe, H; Grass, U; Häussler, B; Höer, A; Schiffhorst, G; Sterzel, A, 2007) |
| "To estimate the net cardiovascular (CV) (coronary heart disease, stroke, congestive heart failure), and gastrointestinal (GI) (peptic ulcer complications) risk-benefit public health impact of the use of celecoxib compared to non-selective NSAIDs in the arthritis population." | 3.74 | Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level. ( Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C, 2007) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 3.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| " Patients with a history of peptic ulcers were randomized to 1-week omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg twice daily (eradication group; n = 51) or 1-week omeprazole 20 mg twice daily (omeprazole group; n = 49) before initiation of diclofenac 100 mg daily for 6 months." | 3.73 | Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis. ( Chan, FK; Ching, JY; Lau, W; Lee, IY; Lee, KK; You, JH; Yung, M, 2006) |
| " Adverse effects were significantly less in curcuminoid complex plus diclofenac group (13% vs 38% in diclofenac group; P < ." | 2.94 | Efficacy and safety of combination of curcuminoid complex and diclofenac versus diclofenac in knee osteoarthritis: A randomized trial. ( Gade, P; Karad, S; Khanwelkar, C; Shep, D, 2020) |
| " Evaluation of the profile of adverse events was the main aim of the trial, together with assessment of efficacy." | 2.69 | Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. ( Alegre, C; Baumelou, E; Bégaud, B; Dequeker, J; Hawkey, C; Isomäki, H; Kahan, A; Littlejohn, G; Mau, J; Papazoglou, S; Steinbrück, K, 1998) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| ", was given during the second week of each dosage regimen after three endoscopic biopsies had been taken from each of the duodenum, antrum and corpus." | 2.68 | Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers. ( Armstrong, D; Blum, AL; Dorta, G; Margalith, D; Nicolet, M; Saraga, E; Vouillamoz, D, 1996) |
| "Interindividual variability in drug metabolism is an important cause of adverse drug reactions and variability in drug efficiency." | 2.53 | How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity. ( Bilić, I; Božina, N; Dimovski, A; Domjanović, IK; Krasniqi, V, 2016) |
| "Cyclo-oxygenase (COX)-2 selective inhibitors (coxibs) were designed to reduce the incidence of gastrointestinal (GI) adverse events (AEs) which occur with non-selective NSAIDs (ns-NSAIDs)." | 2.44 | Global gastrointestinal safety profile of etoricoxib and lumiracoxib. ( Hunt, RH; Yuan, Y, 2007) |
| " One of the main DCF metabolites is a reactive diclofenac acyl glucuronide (DCF-AG) that covalently binds to biologic targets and may contribute to adverse drug reactions arising from DCF use." | 1.42 | Multidrug Resistance-Associated Protein 3 Plays an Important Role in Protection against Acute Toxicity of Diclofenac. ( Csanaky, IL; Goedken, MJ; Manautou, JE; Scialis, RJ, 2015) |
| "Diclofenac can cause gastric mucosal lesions, including ulcers, more easily than other NSAIDs." | 1.34 | Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. ( Fukui, H; Takakura, Y; Yajima, H; Yamao, J, 2007) |
| "Diclofenac and aspirin were most common NSAIDs associated with peptic ulcers in 32." | 1.33 | Frequency of NSAID induced peptic ulcer disease. ( Abid, S; Hamid, S; Islam, M; Islam, S; Jafri, W; Yakoob, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (2.99) | 18.7374 |
| 1990's | 13 (19.40) | 18.2507 |
| 2000's | 40 (59.70) | 29.6817 |
| 2010's | 11 (16.42) | 24.3611 |
| 2020's | 1 (1.49) | 2.80 |
| Authors | Studies |
|---|---|
| Shep, D | 1 |
| Khanwelkar, C | 1 |
| Gade, P | 1 |
| Karad, S | 1 |
| Sugano, K | 1 |
| Kinoshita, Y | 1 |
| Miwa, H | 1 |
| Takeuchi, T | 2 |
| Kuramoto, T | 1 |
| Umegaki, E | 1 |
| Nouda, S | 1 |
| Narabayashi, K | 1 |
| Kojima, Y | 1 |
| Yoda, Y | 1 |
| Ishida, K | 1 |
| Kawakami, K | 1 |
| Abe, Y | 1 |
| Inoue, T | 1 |
| Murano, M | 1 |
| Tokioka, S | 1 |
| Higuchi, K | 1 |
| Lee, OY | 1 |
| Kang, DH | 1 |
| Lee, DH | 1 |
| Chung, IK | 1 |
| Jang, JY | 2 |
| Kim, JI | 1 |
| Cho, JW | 1 |
| Rew, JS | 1 |
| Lee, KM | 1 |
| Kim, KO | 1 |
| Choi, MG | 1 |
| Lee, SW | 1 |
| Lee, ST | 1 |
| Kim, TO | 1 |
| Shin, YW | 1 |
| Seol, SY | 1 |
| Scialis, RJ | 1 |
| Csanaky, IL | 1 |
| Goedken, MJ | 1 |
| Manautou, JE | 1 |
| Krasniqi, V | 1 |
| Dimovski, A | 1 |
| Domjanović, IK | 1 |
| Bilić, I | 1 |
| Božina, N | 1 |
| Niwa, Y | 1 |
| Nakamura, M | 1 |
| Miyahara, R | 1 |
| Ohmiya, N | 1 |
| Watanabe, O | 1 |
| Ando, T | 1 |
| Kawashima, H | 1 |
| Itoh, A | 1 |
| Hirooka, Y | 1 |
| Goto, H | 1 |
| Romero Vázquez, J | 1 |
| Herrerías Gutiérrez, JM | 1 |
| Cheung, R | 1 |
| Cheng, TT | 1 |
| Dong, Y | 1 |
| Lin, HY | 1 |
| Lai, K | 1 |
| Lau, CS | 1 |
| Feng, H | 1 |
| Parsons, B | 1 |
| Chan, FK | 5 |
| Lanas, A | 1 |
| Scheiman, J | 1 |
| Berger, MF | 1 |
| Nguyen, H | 1 |
| Goldstein, JL | 2 |
| Van Landeghem, L | 1 |
| Chevalier, J | 1 |
| Mahé, MM | 1 |
| Wedel, T | 1 |
| Urvil, P | 1 |
| Derkinderen, P | 1 |
| Savidge, T | 1 |
| Neunlist, M | 1 |
| Drozdov, VN | 1 |
| Kim, VA | 1 |
| Lazebnik, LB | 1 |
| Niebling, W | 1 |
| McCormack, JP | 1 |
| Rangno, R | 1 |
| Geis, GS | 5 |
| Labenz, J | 2 |
| Blum, AL | 2 |
| Bolten, WW | 1 |
| Dragosics, B | 1 |
| Rösch, W | 1 |
| Stolte, M | 1 |
| Koelz, HR | 1 |
| Sikes, DH | 1 |
| Agrawal, NM | 4 |
| Zhao, WW | 2 |
| Kent, JD | 2 |
| Recker, DP | 2 |
| Verburg, KM | 3 |
| Englev, E | 1 |
| Christensen, KB | 1 |
| Graham, DY | 1 |
| Tachibana, M | 1 |
| Inoue, N | 1 |
| Yoshida, E | 1 |
| Matsui, M | 1 |
| Ukai, Y | 1 |
| Yano, J | 1 |
| Pavelka, K | 1 |
| von Scheele, B | 1 |
| Peña, B | 1 |
| Wong, J | 1 |
| Niculescu, L | 2 |
| Kivitz, AJ | 2 |
| Nayiager, S | 1 |
| Schimansky, T | 1 |
| Gimona, A | 1 |
| Thurston, HJ | 1 |
| Hawkey, C | 2 |
| Hawkey, CJ | 2 |
| Farkouh, M | 1 |
| Gitton, X | 2 |
| Ehrsam, E | 1 |
| Huels, J | 1 |
| Richardson, P | 1 |
| Hawkey, CC | 1 |
| Svoboda, P | 1 |
| Fiedorowicz-Fabrycy, IF | 1 |
| Nasonov, EL | 1 |
| Pikhlak, EG | 1 |
| Cousin, M | 1 |
| Hoexter, G | 1 |
| Hung, LC | 1 |
| Suen, BY | 1 |
| Wong, VW | 1 |
| Hui, AJ | 1 |
| Wu, JC | 2 |
| Leung, WK | 2 |
| Lee, YT | 1 |
| To, KF | 2 |
| Chung, SC | 1 |
| Sung, JJ | 2 |
| Cryer, B | 2 |
| Hollenz, M | 1 |
| McCarthy, DM | 1 |
| Ashworth, NL | 1 |
| Peloso, PM | 1 |
| Muhajarine, N | 1 |
| Stang, M | 1 |
| You, JH | 1 |
| Lau, W | 1 |
| Lee, IY | 1 |
| Yung, M | 1 |
| Ching, JY | 1 |
| Lee, KK | 1 |
| Hamid, S | 1 |
| Yakoob, J | 1 |
| Jafri, W | 1 |
| Islam, S | 1 |
| Abid, S | 1 |
| Islam, M | 1 |
| Varas-Lorenzo, C | 1 |
| Maguire, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Laine, L | 1 |
| Curtis, SP | 1 |
| Kaur, A | 1 |
| Cannon, CP | 1 |
| Höer, A | 1 |
| Gothe, H | 1 |
| Schiffhorst, G | 1 |
| Sterzel, A | 1 |
| Grass, U | 1 |
| Häussler, B | 1 |
| Parashar, A | 1 |
| Einecke, D | 1 |
| Krüger, K | 1 |
| Yajima, H | 1 |
| Yamao, J | 1 |
| Fukui, H | 1 |
| Takakura, Y | 1 |
| Bannwarth, B | 1 |
| Bérenbaum, F | 1 |
| Pilotto, A | 1 |
| Seripa, D | 1 |
| Franceschi, M | 1 |
| Scarcelli, C | 1 |
| Colaizzo, D | 1 |
| Grandone, E | 1 |
| Niro, V | 1 |
| Andriulli, A | 1 |
| Leandro, G | 1 |
| Di Mario, F | 1 |
| Dallapiccola, B | 1 |
| Yuan, Y | 1 |
| Hunt, RH | 1 |
| Peura, D | 1 |
| Wilcox, CM | 1 |
| Berger, M | 1 |
| Van Kerckhove, HE | 1 |
| Erhardt, LJ | 1 |
| Cullen, D | 1 |
| Melo Gomes, JA | 1 |
| Roth, SH | 1 |
| Zeeh, J | 1 |
| Bruyn, GA | 1 |
| Woods, EM | 1 |
| Giannoukas, AD | 1 |
| Baltoyiannis, G | 1 |
| Milonakis, M | 1 |
| Nastos, D | 1 |
| Papagikos, L | 1 |
| Kappas, AM | 1 |
| Fatouros, M | 1 |
| Papadimitriou, C | 1 |
| Cassioumis, D | 1 |
| Dorta, G | 1 |
| Nicolet, M | 1 |
| Vouillamoz, D | 1 |
| Margalith, D | 1 |
| Armstrong, D | 1 |
| Saraga, E | 1 |
| Silverstein, FE | 2 |
| Bianchi Porro, G | 1 |
| Lazzaroni, M | 1 |
| Petrillo, M | 1 |
| Manzionna, G | 1 |
| Montrone, F | 1 |
| Caruso, I | 1 |
| Kahan, A | 1 |
| Steinbrück, K | 1 |
| Alegre, C | 1 |
| Baumelou, E | 1 |
| Bégaud, B | 1 |
| Dequeker, J | 1 |
| Isomäki, H | 1 |
| Littlejohn, G | 1 |
| Mau, J | 1 |
| Papazoglou, S | 1 |
| Al, MJ | 1 |
| Michel, BC | 1 |
| Rutten, FF | 1 |
| Caldwell, J | 1 |
| Weaver, AL | 1 |
| Bocanegra, TS | 1 |
| Ball, J | 1 |
| Dhadda, S | 1 |
| Hurley, S | 1 |
| Hancock, L | 1 |
| Plosker, GL | 1 |
| Lamb, HM | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Faich, G | 1 |
| Simon, LS | 1 |
| Pincus, T | 1 |
| Whelton, A | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Stenson, WF | 1 |
| Burr, AM | 1 |
| Lefkowith, JB | 1 |
| Morgan , GJ | 1 |
| Kaine, J | 1 |
| DeLapp, R | 1 |
| Palmer, R | 1 |
| Tive, L | 1 |
| Dobrilla, G | 1 |
| Tsokos, M | 1 |
| Schmoldt, A | 1 |
| Yung, MY | 1 |
| Kwok, T | 1 |
| Hui, Y | 1 |
| Chan, HL | 1 |
| Chan, CS | 1 |
| Hui, E | 1 |
| Woo, J | 1 |
| Wildgrube, HJ | 1 |
| Kierschke, G | 1 |
| Nowak, H | 1 |
| Weigmann, I | 1 |
| Terhaag, B | 1 |
| Bolten, W | 1 |
| Gomes, JA | 1 |
| Stead, H | 1 |
| Caldwell, JR | 1 |
| O'brien, WM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use[NCT00595517] | Phase 3 | 395 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At Hig[NCT00141102] | Phase 4 | 4,484 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Tolerability and Effectiveness of Etoricoxib 90 mg q.d. vs. Diclofenac Sodium 50 mg t.i.d. in Patients With Osteoarthritis[NCT00092703] | Phase 3 | 6,000 participants | Interventional | 2002-06-27 | Completed | ||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191] | Phase 3 | 528 participants (Actual) | Interventional | 2003-02-05 | Completed | ||
| A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study to Evaluate the Safety of Etoricoxib in Patients With Osteoarthritis or Rheumatoid Arthritis[NCT00250445] | Phase 3 | 23,498 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00595517)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 125 |
(NCT00595517)
Timeframe: up to 12 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 127 |
(NCT00595517)
Timeframe: up to 24 weeks after treatment
| Intervention | participants (Number) |
|---|---|
| Esomeprazole 20mg | 126 |
(NCT00595517)
Timeframe: up to 4 weeks after treatment
| Intervention | Participants (Number) |
|---|---|
| Esomeprazole 20mg | 130 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 0.058 |
| Oral Diclofenac Plus Omeprazole | 0.073 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | ug/dL (Least Squares Mean) |
|---|---|
| Celecoxib | -3.396 |
| Oral Diclofenac Plus Omeprazole | -1.990 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | percent (Least Squares Mean) |
|---|---|
| Celecoxib | -0.306 |
| Oral Diclofenac Plus Omeprazole | -1.425 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | grams (g)/deciliter (dL) (Least Squares Mean) |
|---|---|
| Celecoxib | -0.017 |
| Oral Diclofenac Plus Omeprazole | -0.423 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | microgram (ug)/dL (Least Squares Mean) |
|---|---|
| Celecoxib | 2.517 |
| Oral Diclofenac Plus Omeprazole | 1.952 |
"Subjects rated response to question: Considering all the ways the osteoarthritis or rheumatoid arthritis affects you, how are you doing today? using a 1 to 5 grading scale where 1=very good and 5=very poor." (NCT00141102)
Timeframe: Month 6/Early Termination (ET)
| Intervention | scores on a scale (Least Squares Mean) |
|---|---|
| Celecoxib | 0.754 |
| Oral Diclofenac Plus Omeprazole | 0.773 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 2018 |
| Oral Diclofenac Plus Omeprazole | 2023 |
Interview occurred via telephone to obtain follow-up mortality and hospitalization information. (NCT00141102)
Timeframe: 6 months following last dose
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 82 |
| Oral Diclofenac Plus Omeprazole | 79 |
A clinically significant decrease from baseline was defined as a fall in hematocrit > = 10 percentage points and/or hemoglobin > = 2 g/dL. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 45 |
| Oral Diclofenac Plus Omeprazole | 123 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 20 |
| Oral Diclofenac Plus Omeprazole | 81 |
CSULGIE=any of the following: GD hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 25 |
| Oral Diclofenac Plus Omeprazole | 92 |
"Abdominal symptoms were defined by the Medical Dictionary for Regulatory Activities MedDRA System Organ Class (SOC) 'Gastrointestinal Disorders' and keeping high level group term (HLGT) equal to Gastrointestinal Signs and Symptoms." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 132 |
| Oral Diclofenac Plus Omeprazole | 162 |
Subjects with evaluation at an event visit and found to have an ulcer on endoscopy, but did not meet any criteria considered for the primary endpoint by the GI committee were designated as having an SU. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 5 |
| Oral Diclofenac Plus Omeprazole | 11 |
"GI AEs were defined using MedDRA SOC Gastrointestinal Disorders but excluding the following HLGTs: Benign Neoplasms Gastrointestinal; Dental and Gingival Conditions; Oral Soft Tissue Conditions; Salivary Gland Conditions; and Tongue Conditions." (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) |
|---|---|
| Celecoxib | 114 |
| Oral Diclofenac Plus Omeprazole | 167 |
(NCT00141102)
Timeframe: Month 6/ET
| Intervention | IU/L (Least Squares Mean) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | -2.689 | -0.901 | -1.151 |
| Oral Diclofenac Plus Omeprazole | 7.455 | 1.490 | 5.213 |
CSULGIE=any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; clinically significant anemia of defined GI origin; acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage; clinically significant anemia of presumed occult GI origin including possible small bowel blood loss. Subjects were assessed by an independent GI Events Adjudication Committee, who were blinded to study treatment assignments. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | |
|---|---|---|
| History of GD Ulceration (n=395, 400) | No History of GD Ulceration (n=1843, 1846) | |
| Celecoxib | 7 | 13 |
| Oral Diclofenac Plus Omeprazole | 13 | 68 |
GGT ULN was 49 international units (IU)/liter (L) for females and 61 IU/L for males, AST ULN was 37 IU/L for females and 39 IU/L for males, and ALT ULN was 43 IU/L for females and 45 IU/L for males. (NCT00141102)
Timeframe: 6 month treatment duration
| Intervention | participants (Number) | ||
|---|---|---|---|
| GGT | AST | ALT | |
| Celecoxib | 26 | 8 | 13 |
| Oral Diclofenac Plus Omeprazole | 86 | 12 | 27 |
9 reviews available for diclofenac and Peptic Ulcer
| Article | Year |
|---|---|
How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cytochrome P-450 CYP2C8; Cytochrome P-450 Enzyme System; Di | 2016 |
Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cyclooxygenase Inhibitors; Diclofenac; Gas | 2002 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Aspirin; Cyclooxyge | 2007 |
Lumiracoxib in the management of osteoarthritis and acute pain.
Topics: Acute Disease; Animals; Cardiovascular Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Appro | 2007 |
Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Interactions; | 2007 |
Improving the gastrointestinal safety of NSAIDs: the development of misoprostol--from hypothesis to clinical practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Diclofenac; Drug Combinations | 1998 |
Diclofenac/misoprostol. Pharmacoeconomic implications of therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Costs and Cost Analysis; Diclofenac; Dru | 1999 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
30 trials available for diclofenac and Peptic Ulcer
| Article | Year |
|---|---|
Efficacy and safety of combination of curcuminoid complex and diclofenac versus diclofenac in knee osteoarthritis: A randomized trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Curcuma; Diarylheptanoids; Diclofenac; Female; Histamine H2 | 2020 |
Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Diclofenac; Esomeprazole; Fema | 2013 |
Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Endoscopy, Gastrointe | 2013 |
A comparative study of DA-9601 and misoprostol for prevention of NSAID-associated gastroduodenal injury in patients undergoing chronic NSAID treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Double-Blind Me | 2014 |
Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: a prospective randomized placebo-controlled double-blind cross-over study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 2009 |
Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; China; Comorbidity; Cy | 2010 |
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Celecoxib; | 2010 |
[Modern approach to the prevention and treatment of NSAID-gastropathy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Famotidine; Gastric Mucosa; | 2011 |
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.
Topics: Adult; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clarithromycin; Dicl | 2002 |
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclo | 2002 |
Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclo | 2003 |
Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cohort Studies; Cost Sa | 2003 |
Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygen | 2004 |
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 In | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study.
Topics: Arthritis, Rheumatoid; Diclofenac; Endoscopy, Gastrointestinal; Female; Humans; Incidence; Life Tabl | 1995 |
Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Diclofenac; Double-Blind Method; Drug Combinations; Drug Therapy, Co | 1993 |
Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biopsy; Cross-Over Studies; Diclo | 1996 |
Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Double-Blind Method; Endosco | 1998 |
Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind M | 1998 |
The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis.
Topics: Age Factors; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthr | 1996 |
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Double-Blind Method; Dr | 1999 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; D | 2001 |
[Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 2001 |
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Delayed-Action Preparations; | 2002 |
[Application of quantifying scoring systems for the determination of changes in the mucosa of the upper gastrointestinal tract. A comparative study of a diclofenac effervescent tablet with conventional diclofenac preparations and acetylsalicylic acid afte
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclofenac; Drug Combinations; Endoscopy; F | 2002 |
The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis.
Topics: Adult; Aged; Diclofenac; Double-Blind Method; Drug Combinations; Duodenum; Female; Gastrointestinal | 1992 |
Efficacy and safety of diclofenac sodium in rheumatoid arthritis. Experience in the United States.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Diclofenac; Double-Blind Meth | 1986 |
28 other studies available for diclofenac and Peptic Ulcer
| Article | Year |
|---|---|
Multidrug Resistance-Associated Protein 3 Plays an Important Role in Protection against Acute Toxicity of Diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; ATP Binding Cassette Transporter, Subfamily B; Bil | 2015 |
Capsule endoscopy and nonsteroidal anti-inflammatory drugs (NSAID)-induced enteropathy--a bit of light in a long, dark tunel.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Capsule Endoscopy; Clinical Trials as To | 2010 |
Enteric glia promote intestinal mucosal healing via activation of focal adhesion kinase and release of proEGF.
Topics: Analysis of Variance; Animals; Caco-2 Cells; Cell Shape; Coculture Techniques; Culture Media, Condit | 2011 |
[Bringing evidence to practice: obstacles and barriers].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comparative Effectiveness Research; Conflict of | 2011 |
Digging for data from the COX-2 trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Random | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenas | 2002 |
[Celecoxib and the CLASS trial].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medic | 2002 |
Celecoxib and the CLASS trial: data massaging by industry.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclof | 2002 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cyclooxygenase Inhibitors; Diclofenac; | 2003 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2004 |
[Gastrointestinal complications under NSAID treatment in the doctor's office].
Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Clinical Trials as Topic; Dicl | 2004 |
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cohort Studies; Databas | 2005 |
Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2006 |
Frequency of NSAID induced peptic ulcer disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diclof | 2006 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular D | 2007 |
Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Case-Control Studies; Datab | 2007 |
Gastrointestinal safety of NSAIDs versus COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Gastroin | 2007 |
[Coronary risks with NSAID and coxibs. The end of hysteria].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cause | 2006 |
[3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygen | 2006 |
Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis.
Topics: Adult; Aged; Alanine; Anti-Ulcer Agents; Bone Diseases; Cyclooxygenase 2 Inhibitors; Diclofenac; End | 2007 |
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cas | 2007 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans | 2008 |
Arthrotec for all?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Drug Combinations; Female; Humans; Misopr | 1993 |
Protection of the gastroduodenal mucosa from the effects of diclofenac sodium: role of highly selective vagotomy and misoprostol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Combined Modality Therapy; Dicl | 1996 |
Nitric oxide and non steroidal antiinflammatory drugs (NSAID)-related gastroduodenal damage.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Gastric Mucosa; Glycine; Humans; Nitri | 2001 |
Contribution of nonsteroidal anti-inflammatory drugs to deaths associated with peptic ulcer disease: a prospective toxicological analysis of autopsy blood samples.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Chromatogra | 2001 |
Adverse reactions to nonsteroidal anti-inflammatory drugs. Diclofenac compared with other nonsteroidal anti-inflammatory drugs.
Topics: Aged; Anaphylaxis; Anemia, Aplastic; Anti-Inflammatory Agents; Asthma; Blood Platelets; Chemical and | 1986 |